Back to today’s briefing

Story perspectives

BridgeBio Pharma Surpasses Revenue Estimates Amid FDA Approval

2/23/2025

50 6

Summary

Story summary

Analyst Mani Foroohar has a Buy rating on BridgeBio Pharma (BBIO) based on strong demand for Attruby and positive pipeline progress.
BBIO's Q4 2024 revenue reached $5.9 million, surpassing estimates, with total annual revenue at $221.9 million.
The company reported a Q4 net loss of $265.1 million but retains $681 million in cash for R&D.
The FDA approved Attruby, with over 1,000 prescriptions written, showcasing significant market potential.

1 of 1

Story summary

Analyst Mani Foroohar has a Buy rating on BridgeBio Pharma (BBIO) based on strong demand for Attruby and positive pipeline progress.
BBIO's Q4 2024 revenue reached $5.9 million, surpassing estimates, with total annual revenue at $221.9 million.
The company reported a Q4 net loss of $265.1 million but retains $681 million in cash for R&D.
The FDA approved Attruby, with over 1,000 prescriptions written, showcasing significant market potential.